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RNA and Peptide Synthesis 
 Peptides were generated on an Applied Biosystems 432A peptide synthesizer using solid phase, F-Moc chemistry. Crude peptides were 
deprotected by TFA/ethanedithiol/thioanisole treatment and purified on a C-18 reverse phase HPLC column to a final purity greater than 
95% (MALDI-TOF, Analytical C-18 HPLC). Peptides without a naturally occurring tryptophan or tyrosine residue were synthesized with 
a carboxy-terminal Gly-Tyr tag for quantification purposes.  
Unlabeled RNA hairpins (λboxBR15 and P22boxBL15) were synthesized by in vitro transcription using T7 RNA polymerase.1 The RNA 
was purified by 20% urea-PAGE, desalted on a NAP column (Amersham Pharmacia), and freeze-dried. RNA was quantified by UV 
absorption at a wavelength of 260 nm. 
Labeled RNA hairpins containing 2-amino purine (2AP) at loop position 2 (2AP-2), 3 (2AP-3), or 4 (2AP-4) were constructed by 
automated RNA synthesis using either 2-aminopurine-TOM-CE phosphoramidite or 2’-O-methyl 2-aminopurine phosphoramidite (Glen 
Research, Sterling, VA). 
 
Steady-State Fluorescence Measurements 
Measurements were conducted following the procedures of Barrick et. al.2 Titrations were performed on a Shimadzu 
Spectrofluorophotometer at 20º C with Excitation/Emission wavelengths at 310/370 nm . Peptides were titrated iteratively into a 
constantly stirred solution of 2AP labeled RNA hairpin (20-200 nM RNA). Binding buffer contained 20 mM Tris-OAc, with a variable 
concentration of KOAc (15 mM-500 mM) at pH 7.5. Binding Constants were calculated for a one step binding mechanism by nonlinear 
least squares regression using the computer program DynaFit.3 All isotherms were fit with < 10% uncertainty. Relative 2AP fluorescence 
change (F) is reported as a fraction; F = (FF/FO) where FO and FF are the initial and final fluorescence respectively. Binding constants 
required a change in fluorescence of greater than 10% for reliable fitting. Salt dependence values (-δlogKobs)(δlog[M+])-1 were determined 
from five or more binding constants within a range of salt concentrations (50-500mM KOAc). 
 
Stopped-Flow Fluorescence Measurements  
Experiments were conducted following the procedures of Lacourciere et al.4 Measurements were performed at 20º C under standard 
buffer conditions (20 mM Tris-OAc, 50 mM KOAc, pH 7.5) using a stop-flow device from Applied Photophysics (Surray, U.K.) in two-
syringe mode. Fluorescence excitation was performed at 310 nm and emmision was measured with a filter cutoff > 360 nm. The 
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association rate (kon) was determined for the λN22-λboxB complex to be 7 x 108 s-1M-1. A similar rate was observed for the P22N21-
P22boxB complex. Dissociation rate values (koff) were determined for each interaction by infusing labeled complex with both 100x and 
500x concentration of unlabeled competitor boxB at time zero.   
 
Circular Dichroism Spectroscopy 
Spectra were recorded on an Aviv 62 DS CD spectrofluorimeter in 10 mM potassium phosphate buffer at 20º C. Spectra for the peptide-
RNA complexes were determined by subtracting spectra with the equivalent concentrations of RNA and of peptide from the spectra of the 
complex. Helix content was calculated from ellipticity at 222 nm (θ222), using –40,000(1-2.5/n) and 0 deg cm2 dmol-1 as values for θhelix222 
and θcoil222 respectively (n is the number of amino acids in the peptide).5 Helicity = (θobserved)/(θhelix + θaromatic). The contribution of Trp was 
assumed to be –2300 ± 600 (θaromatic) while the GY tag of the P22N21was assumed to contribute insignificant helicity and aromaticity to the 
CD spectrum.6  
 
 NMR Spectroscopy 
Samples were prepared in NMR buffer: 50 mM NaCl, 10 mM phosphate, pH 6 in H2O:D2O (90:10, vol:vol) as previously described.2 
NMR spectra were collected at 25ºC on a Varian INOVA 600-MHz spectrometer. A modified double gradient echo Watergate solvent-
suppression pulse sequence was used to suppress the solvent peak.7 Assignments were based on reported work.8 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 1. a 
  P22boxB RNA  λboxB RNA 
     Fluorescence (F) 
peptides Kd(70) (pM) koff/kon (pM) Kd(70) (pM) koff/kon (pM) 2AP-2 2AP-3 2AP-4 
        
P22N21 5.0 ± 1.4 12 850 ± 290  1.60 0.53 1.00 
λN22   1,900 ± 690   1,000 0.32 0.22 2.35 
λN22(N2)   170 ± 18 170 0.36 0.15 2.60 
λN22(N2,K4)   97 ± 22 69 0.33 0.21 2.45 
λN22(N2,R4)   23 ± 4.9 17 0.35 0.14 2.50 
λN22(G1,N2,K4)   34 ± 7.9 49 0.35 0.12 2.42 
λN22(G1,N2,R4)   12 ± 3.2  0.32 0.13 2.39 
        
a Dissociation constants (Kd’s) were determined from salt dependence measurements for 2AP-2 labeled complexes at standard salt 
conditions (70 mM [M+]). Salt dependence values δ/δ = (δlogKobs)(δlog[M+])-1 were determined from five or more measurements over a range 
of 50-500 mM KOAc. Individual measurements were fit with < 10% error. Kinetic approximations of dissociation constants, Kd = koff/kon, were 
calculated using a rate of association value, kon = 7 x 108 s-1M-1; rate of dissociation values were fit with < 10% error. 
 
3 
 
 
Supplemental Figure 1. Circular dichroism measurements for 
λN22 and reciprocal mutants in free solution (A) and in complex 
with λboxB (B). Measurements were taken in 10mM phosphate 
buffer at 20ºC. Concentration of peptide in free solution was 
10µM. Peptide-RNA complexes were prepared at 6:5µM 
stoichiometry. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2. NMR imino-spectra of λN22-λboxB 
native and reciprocal complexes. The Trp18 imino-peak shifts 
from 10.0 ppm in the free peptides to 9.2 ppm in the λboxB 
comlex. Samples were prepared in 50 mM NaCl, 10 mM 
phosphate buffer, pH 6 and titrated to 1:1 stoichiometry at 25ºC.  
Assignments are based on reported work.8 
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